Smith+Nephew (SNN) announced clinical results for its total hip arthroplasty (THA) portfolio in both the National Joint Registry (NJR) for England, Wales and Northern Ireland and the the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Data indicates that SNN's POLAR3™ Total Hip Solution has the top performing cementless construct components for total hip replacement.
POLAR3 comprises the POLARSTEM™ Cementless Stem, R3™ Acetabular System and OXINIUM™ Technology.
The NJR 2020 annual report showed the latest implant survivorship figures in total joint arthroplasty, in which Smith+Nephew's POLARSTEM and R3 demonstrated:
- The highest implant survivorship (98.46%) of all cementless hip constructs at ten years
- 72% lower revision risk compared to the class average for cementless hip combinations at ten years
Further, the AOANJRR 2020 report showed that OXINIUM Technology (ceramicized metal on XLPE) continued to have the lowest revision rate of all hip bearing combinations at fifteen years, and:
- From one year, significantly reduces the risk of revision compared to Metal/XLPE by 39–41%
- Demonstrated 94.5% survivorship at 15 years
"There are now four prominent registries with mid- to long-term data confirming that our OXINIUM Technology has the highest survivorship," said Vasant Padmanabhan, President Global R&D for Smith+Nephew. "With these milestone results, orthopaedic surgeons can be more confident than ever in recommending POLAR3 as best performing cementless hip construct and bearing combination on the market today to their patients."